company background image
IKT logo

Inhibikase Therapeutics NasdaqCM:IKT Stock Report

Last Price

US$2.36

Market Cap

US$14.6m

7D

-7.8%

1Y

-48.2%

Updated

19 Feb, 2024

Data

Company Financials +

Inhibikase Therapeutics, Inc.

NasdaqCM:IKT Stock Report

Market Cap: US$14.6m

IKT Stock Overview

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.

IKT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Inhibikase Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Inhibikase Therapeutics
Historical stock prices
Current Share PriceUS$2.36
52 Week HighUS$5.61
52 Week LowUS$0.79
Beta1.34
1 Month Change37.25%
3 Month Change151.06%
1 Year Change-48.25%
3 Year Change-94.82%
5 Year Changen/a
Change since IPO-96.03%

Recent News & Updates

Recent updates

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Jan 25
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Aug 26

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Aug 12

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Aug 09
Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06
Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Inhibikase Therapeutics prices stock offering at $3

Jun 16

Shareholder Returns

IKTUS BiotechsUS Market
7D-7.8%0.6%-0.2%
1Y-48.2%4.4%20.5%

Return vs Industry: IKT underperformed the US Biotechs industry which returned 4.8% over the past year.

Return vs Market: IKT underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is IKT's price volatile compared to industry and market?
IKT volatility
IKT Average Weekly Movement19.2%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: IKT's share price has been volatile over the past 3 months.

Volatility Over Time: IKT's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20087Milton Wernerhttps://www.inhibikase.com

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.

Inhibikase Therapeutics, Inc. Fundamentals Summary

How do Inhibikase Therapeutics's earnings and revenue compare to its market cap?
IKT fundamental statistics
Market capUS$14.60m
Earnings (TTM)-US$19.13m
Revenue (TTM)US$324.07k

45.1x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IKT income statement (TTM)
RevenueUS$324.07k
Cost of RevenueUS$13.67m
Gross Profit-US$13.35m
Other ExpensesUS$5.78m
Earnings-US$19.13m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.09
Gross Margin-4,118.13%
Net Profit Margin-5,903.12%
Debt/Equity Ratio0%

How did IKT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.